Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

20.98 -0.32 (-1.50%)
Streaming Delayed Price Updated: 10:54 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adma Biologics

< Previous 1 2 3 4 5 6 7 Next >
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights
Via Benzinga
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
Via Investor's Business Daily
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
Via Benzinga
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024
ADMA stock results show that ADMA Biologics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
Via Benzinga
Forecasting The Future: 4 Analyst Projections For ADMA Biologics
Via Benzinga
Recap: ADMA Biologics Q4 Earnings
Via Benzinga
Earnings Preview For ADMA Biologics
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Chart Of The Day: ADMA Biologics - Hitting New Highs
100% technical buy signals 8 new highs and up 7.24% in the last month 110.10+ Weighted Alpha 
Via Talk Markets
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For ADMA Biologics
Via Benzinga
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces CFO Transition
Executive Search Initiated for CFO Replacement 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Conference Call Scheduled for February 28, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
From ADMA Biologics, Inc.
Via GlobeNewswire
Why Adma Biologics Stock Crushed the Market on Friday
The network of FDA-approved collection facilities continues to grow. 
Via The Motley Fool
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
FDA Approval Signifies the Accomplishment of ADMA’s Corporate Goal of Plasma Supply Self-Sufficiency 
From ADMA Biologics, Inc.
Via GlobeNewswire
Why Adma Biologics Was Trouncing the Market Today
The company beat analyst estimates for both revenue and profitability, and raised revenue guidance. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.